Inotuzumab Ozogamicin

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Inotuzumab Ozogamicin
   1. Pharmacist Assessment Report
   2. Inotuzumab Ozogamicin: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Inotuzumab Ozogamicin: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Inotuzumab Ozogamicin, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
precursor cell lymphoblastic leukemia-lymphoma	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
11668D	Besponsa	Powder for I.V. infusion 1 mg	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Antibody-drug conjugate with a cytotoxic payload (calicheamicin), targeted therapy
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions (myelosuppression and thrombocytopenia are recognised concerns for this class)
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI; typically includes full blood count and liver function
Handling Protection	Follow local cytotoxic drug handling requirements

---

Safety Considerations

• Drug Interactions: The interaction screen returned 100 interacting drugs, and 20 were available for review. Most are Moderate, including famotidine, loperamide, bisacodyl, clarithromycin, levofloxacin, palonosetron, granisetron, and several laxatives and bowel preparations. Two are classed as Major: dolasetron and cisapride. Metronidazole is classed as Minor. Many of the flagged drugs are associated with QT prolongation or electrolyte disturbance.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI) for safety information.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---